Rationale for Targeting CD6 as a Treatment for Autoimmune Diseases.

Rationale for Targeting CD6 as a Treatment for Autoimmune Diseases.

Item
http://www.wikidata.org/entity/Q38730494
Human endogenous retrovirus group E and its involvement in diseasesImmunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumabT cell activation and differentiation is modulated by a CD6 domain 1 antibody ItolizumabImmunological evaluation of rheumatoid arthritis patients treated with itolizumab.Itolizumab - a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasisRelevance of CD6-Mediated Interactions in the Regulation of Peripheral T-Cell Responses and Tolerance.Itolizumab, a novel anti-CD6 monoclonal antibody: a safe and efficacious biologic agent for management of psoriasis.CD318 is a ligand for CD6.Functional implications of disease-specific variants in loci jointly associated with coeliac disease and rheumatoid arthritis.CD6 as a potential target for treating multiple sclerosisRationale for treating primary Sjögren's syndrome patients with an anti-CD6 monoclonal antibody (Itolizumab).Itolizumab (Alzumab), Mogamulizumab (Poteligeo), and Tositumomab (Bexxar)
P2860

Rationale for Targeting CD6 as a Treatment for Autoimmune Diseases.

Item
http://www.wikidata.org/entity/Q38730494
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Rationale for Targeting CD6 as a Treatment for Autoimmune Diseases.
@en
type
label
Rationale for Targeting CD6 as a Treatment for Autoimmune Diseases.
@en
prefLabel
Rationale for Targeting CD6 as a Treatment for Autoimmune Diseases.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P478
P50
P577
P5875
P698
P932
P356
P1433
P1476
Rationale for Targeting CD6 as a Treatment for Autoimmune Diseases.
@en
P2093
P2860
P304
P31
P356
P478
P50
P577
P5875
P698
P932